Acadia falls as rare disease therapy fails late-stage trial
View all comments(0)
Shares of drugmaker Acadia Pharmaceuticals ACAD.O fall 14.8% to $20.1
Co says its experimental therapy to treat a rare metabolic condition failed to meet main goal in late-stage study
ACAD was testing treatment ACP-101 to treat hyperphagia, or feelings of intense and persistent hunger, in patients with genetic disorder called Prader-Willi syndrome
Says co does not plan to investigate therapy any further
Shares of rival drugmaker Soleno Therapeutics SLNO.O rose 12.2%
Including session's move, ACAD up 12.8% and SLNO up 44.6% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
Why SanDisk Stock Could Soar to $4,000?

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

AI Chip Sector Adds Heavyweight Player, Nvidia Rival Cerebras Plans to List Next Week, Targeting Largest US IPO of the Year

Tradingkey







Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.